Bentley Systems and SMRT Trains Collaborate to Improve Safety and Reliability of Metro Rail Services in Singapore
12.10.2021 04:00:00 EEST | Business Wire | Press release
Bentley Systems, Incorporated (Nasdaq:BSY), the infrastructure engineering software company, and SMRT Trains, the pioneer Mass Rapid Transit (MRT) operator in Singapore, have successfully completed the implementation of a Predictive Decision Support System (PDSS) for Singapore’s North-South and East-West lines, the oldest MRT lines in the country. SMRT Trains’ PDSS, which is based on Bentley’s AssetWise Linear Analytics, contributes to improving the reliability of the two lines across 282 kilometers of track and has helped SMRT Trains achieve more than 1 million kilometers between failure (MKBF). MKBF is a measure of reliability used by train operators around the world, where a failure is defined as a service delay of more than five minutes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005442/en/
Kaushik Chakraborty, vice president, Bentley Asia South, and Gan Boon Jin, president of Strides Engineering, at the MOU signing ceremony. (Photo: Business Wire)
Based on the success of the PDSS implementation on the North-South and East-West lines, SMRT Trains has started the implementation of the PDSS solution on the Circle Line (CCL) in Singapore.
With many owner-operators of large metro networks in Asia Pacific cities focusing on improving reliability to provide uninterrupted services to riders, Bentley Systems and Strides Engineering, previously SMRT Services, a business arm of SMRT Corporation that provides a range of station-based engineering services, announced the signing of a Memorandum of Understanding (MOU) to jointly market a rail predictive maintenance solution in the Asia Pacific region. The MOU establishes a partnership between the two companies that combines strong technology expertise and rail operational capabilities to help urban rail and metro operators. Under the terms of the MOU, both organizations will market a rail predictive maintenance solution that visualizes all rail asset information and manages, monitors, and analyzes rail conditions. Bentley Systems will continue to sell, implement, and support its AssetWise solution while Strides Engineering will market and deliver its domain experience and add-on applications for track maintenance.
SMRT Trains will be featured in an Infrastructure Spotlight Series webinar in November as a part of Bentley Systems’ Year in Infrastructure 2021 presentations highlighting advancements in going digital. Registration details will be available soon for this session on yii.bentley.com to learn more about how SMRT Trains is an innovator to watch.
Lam Sheau Kai, president of SMRT Trains, said, “Leveraging technology and taking pre-emptive actions are two very important components in the plan to help us improve and maintain rail reliability for the train lines SMRT Trains operates. PDSS represents both components, and its successful implementation for the North-South and East-West lines has given us much confidence to scale it for the rest of our lines.”
Commenting on the new partnership, Gan Boon Jin, president of Strides Engineering, said, “Strides Engineering’s collaboration with Bentley Systems on the PDSS demonstrates a firm partnership in combining strong domain and rail operational capabilities with proven technological expertise. The PDSS will enhance and optimize decision-making in rail maintenance. We look forward to bringing the best practices and results of PDSS to other train operators in the region.”
Kaushik Chakraborty, vice president, Bentley Asia South, said, “We are extremely happy and honored to partner with Strides Engineering to forward our common objective of advancing infrastructure. With our combined strengths and industry experience, we will empower rail and metro operators in the region to improve reliability of the infrastructure that serves citizens and residents.”
##
About SMRT Trains
SMRT Trains Ltd is the first and largest train services provider in Singapore. As a subsidiary of SMRT Corporation Ltd, we manage and operate train services on the North-South Line, East-West Line, the Circle Line, the new Thomson-East Coast Line and the Bukit Panjang Light Rail Transit.
We have set our core values to be Respect, Integrity, Service and Safety, and Excellence. SMRT Trains is committed to provide safe, reliable and comfortable service.
About Strides Engineering
Advanced Innovative Technologies & Digital Solutions
Strides Engineering, a business arm of SMRT Corporation Limited, has deep, proven experience in exploiting advanced innovative technologies as well as digital solutions and services to deliver safety, reliability, and comfort for commuters.
About Bentley Systems
Bentley Systems (Nasdaq:BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, mining, and industrial facilities. Our offerings include MicroStation-based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, Seequent’s leading geosciences software portfolio, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,000 colleagues and generates annual revenues of more than $800 million in 172 countries.
© 2021 Bentley Systems, Incorporated. Bentley, the Bentley logo, AssetWise, AssetWise Linear Analytics, iTwin, MicroStation, ProjectWise, and Seequent are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005442/en/
Contact information
Press:
Christine Byrne
+1 203 805 0432
Christine.Byrne@bentley.com
Follow us on Twitter:
@BentleySystems
SMRT Corporate Communications
+65 9822 0902
media@smrt.com.sg
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
